Key takeaways
Steglatro (ertugliflozin) and Jardiance (empagliflozin) are both medications in the sodium-glucose cotransporter 2 (SGLT2) inhibitor class used to treat Type 2 diabetes. They help lower blood sugar by preventing sugar from being reabsorbed into the body through the kidneys, causing it to be removed in the urine. While both medications are taken orally once a day, they have some differences. Steglatro is only approved for Type 2 diabetes, whereas Jardiance is also approved to reduce the risk of heart-related complications and worsening kidney problems in certain adults. Jardiance can be used in people as young as 10 years old, while Steglatro is for adults only. The typical starting dose for Steglatro is 5 mg, which can be increased to 15 mg, while Jardiance starts at 10 mg and can be increased to 25 mg. Both medications can cause urinary tract infections, yeast infections, and increased urination. Neither medication is currently available as a lower-cost generic.
